[1] |
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy [J]. J Clin Oncol, 2015, 33(17): 1974-1982.
|
[2] |
Marin-Acevedo JA, Chirila RM, Dronca RS. Immune checkpoint inhibitor toxicities [J]. Mayo Clin Proc, 2019, 94(7): 1321-1329.
|
[3] |
Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in treg development and their involvement in autoimmunity onset and cancer progression [J]. Front Immunol, 2018, 9: 2374.
|
[4] |
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 [J]. J Exp Med, 2012, 209(6): 1201-1217.
|
[5] |
Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors [J]. Int Immunopharmacol, 2018, 62: 29-39.
|
[6] |
Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor [J]. Immunity, 1999, 11(2): 141-151.
|
[7] |
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 [J]. Science, 1995, 270(5238): 985-988.
|
[8] |
Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases [J]. J immunol, 1999, 162(7): 4328-4335.
|
[9] |
Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans [J]. Nat Genet, 2002, 32(4): 666-669.
|
[10] |
Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab [J]. Ann Oncol, 2017, 28(2): 368-376.
|
[11] |
Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports [J]. PLoS One, 2016, 11(7): e0160221.
|
[12] |
Manohar S, Kompotiatis P, Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis [J]. Nephrol Dial Transpl, 2019, 34(1): 108-117.
|
[13] |
Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors [J]. Kidney Int, 2016, 90(3): 638-647.
|
[14] |
Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review [J]. Am J Nephrol, 2017, 45(2): 160-169.
|
[15] |
Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors [J]. Clin J Am Soc Nephrol, 2019, 14(12): 1692-1700.
|
[16] |
Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients [J]. Am J Kidney Dis, 2016, 68(2): 287-291.
|
[17] |
Murakami N, Borges TJ, Yamashita M, et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma [J]. Clin Kidney J, 2016, 9(3): 411-417.
|
[18] |
Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis [J]. N Engl J Med, 2009, 361(2): 211-212.
|
[19] |
Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease [J]. Kidney Int, 2016, 89(3): 720-720.
|
[20] |
Kitchlu A, Fingrut W, Avila-Casado C, et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases [J]. Am J Kidney Dis, 2017, 70(4): 581-585.
|
[21] |
Gallan AJ, Alexander E, Reid P, et al. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors [J]. Am J Kidney Dis, 2019, 74(6): 853-856.
|
[22] |
Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience [J]. J ImmunoTher Cancer, 2019, 7(1): 2.
|
[23] |
Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma [J]. Cancer, 2013, 119(9): 1675-1682.
|
[24] |
Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 [J]. Immunity, 1995, 3(5): 541-547.
|
[25] |
Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1 [J].Crit Rev Immunol, 2004, 24(4): 229-237.
|
[26] |
Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors [J]. Nephrol Dial Transplant, 2017, 32(6): 936-942.
|
[27] |
Koda R, Watanabe H, Tsuchida M, et al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report [J]. BMC Nephrology, 2018, 19(1): 48.
|
[28] |
Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis [J]. J Am Soc Nephrol, 2006, 17(10): 2919-2927.
|
[29] |
Sury K, Perazella MA. The nephrotoxicity of new immunotherapies [J]. Expert Rev Clin Pharmacol, 2019, 12(6): 513-521.
|
[30] |
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline [J]. J Clin Oncol, 2018, 36(17): 1714-1768.
|
[31] |
Krishnan N, Perazella MA. Drug-induced acute interstitial nephritis pathology, pathogenesis and treatment [J]. Iran J Kidney Dis, 2015, 9(1): 3-13.
|
[32] |
Sise ME, Seethapathy H, Reynolds KL. Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review [J]. Oncologist, 2019, 24(6): 735-742.
|
[33] |
Horvat TZ, Adel NG, Thu-Oanh D, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center [J]. J Clin Oncol, 2015, 33(28): 3193-3198.
|
[34] |
Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma [J]. Cancer, 2018, 124(18): 3706-3714.
|
[35] |
Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials [J]. J Clin Oncol, 2017, 35(34): 3807-3814.
|
[36] |
张小红,洪聪敏,邹臻寰,等. 急性肾损伤患者远期肾脏预后的分析[J]. 中华肾脏病杂志,2017, 33(11): 801-807.
|